Tag Archives: Masl

Rowan and Sentrimed University®IN The Biofarmaceutical Company on the clinical stage focused on the development of safer, orally administered oncology therapy, today announced the results from Nation financed by® In patients with oral squamous cell carcinoma (OSCC). The main candidate for the company’s product, Masl, is innovative therapeutic Lekine Licensed at the University of Rowan. […]